Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study.

Leukemia & lymphoma - 1 Dec 2002

Chu Peiguo G, Chen Yuan-Yuan, Molina Arturo, Arber Daniel A, Weiss Lawrence M

Abstract excerpt

Rituximab has been widely used to treat relapsing or advanced stage B-cell neoplasms with an efficacy of about 50%. However, approximately 40-50% of Rituximab treated patients will recur. It is not clear whether these recurrent diseases have the same immunophenotype as that of the original tumors. At the City of Hope, we treated 91 cases of CD20-positive B-cell neoplasms with Rituximab in combination with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived
Share to Antigens, CD20

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Rearrangement, B-Lymphocyte, Heavy Chain

Share to Gene Rearrangement, B-Lymphocyte, Light Chain

Share to Leukemia, B-Cell

Share to Lymphoma, B-Cell

Share to Rituximab

Share to Treatment Failure

Source

Identifiers

PMID: 12613521
DOI: 10.1080/1042819021000040044

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study.PMID 12613521Read ↗

Genetic background and evolution of relapses in aggressive B-cell lymphomas.Semantic proximity Read ↗

Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.Semantic proximity Read ↗

Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.Semantic proximity Read ↗

De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity.Semantic proximity Read ↗

Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's LymphomaSemantic proximity Read ↗

CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure.Semantic proximity Read ↗

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.Semantic proximity Read ↗

Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.Semantic proximity Read ↗

Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.Semantic proximity Read ↗

Rituximab‐induced late onset neutropenia in newly‐diagnosed B‐cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphismSemantic proximity Read ↗

Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma.Semantic proximity Read ↗

Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.